A share price of Replimune Group Inc [REPL] is currently trading at $3.75, up 18.30%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The REPL shares have gain 33.69% over the last week, with a monthly amount drifted -59.81%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Replimune Group Inc [NASDAQ: REPL] stock has seen the most recent analyst activity on July 23, 2025, when H.C. Wainwright downgraded its rating to a Neutral. Previously, BMO Capital Markets downgraded its rating to Underperform on July 23, 2025, and kept the price target unchanged to $2. On July 23, 2025, downgrade downgraded it’s rating to Equal Weight but maintained its price target of $3 on the stock. Wedbush downgraded its rating to a Neutral but stick to its price target of $4 on July 22, 2025. Piper Sandler downgraded its rating to a Neutral but $3 remained the price target by the analyst firm on July 22, 2025. Leerink Partners downgraded its rating to Market Perform for this stock on July 22, 2025, but kept the price target unchanged to $3. In a note dated July 22, 2025, JP Morgan downgraded an Neutral rating on this stock but restated the target price of $9.
Replimune Group Inc experienced fluctuations in its stock price throughout the past year between $2.68 and $17.00. Currently, Wall Street analysts expect the stock to reach $25.5 within the next 12 months. Replimune Group Inc [NASDAQ: REPL] shares were valued at $3.75 at the most recent close of the market. An investor can expect a potential return of 580.0% based on the average REPL price forecast.
Analyzing the REPL fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.45, Equity is -0.58 and Total Capital is -0.47.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.28 points at the first support level, and at 2.82 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.10, and for the 2nd resistance point, it is at 4.46.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Replimune Group Inc [NASDAQ:REPL] is 7.95. Further, the Quick Ratio stands at 7.95.
Transactions by insiders
Recent insider trading involved Astley-Sparke Philip, Director, that happened on May 20 ’25 when 32279.0 shares were sold. Chief Medical Officer, Xynos Konstantinos completed a deal on May 20 ’25 to sell 7952.0 shares. Meanwhile, Chief Accounting Officer Schwendenman Andrew sold 3287.0 shares on May 20 ’25.
